Navigation Links
Investigation of Pharmaceutical Product Development by Securities Lawyers at Goldfarb Branham Law Firm LLP for Potential Shareholder Claim Due to Buyout
Date:10/4/2011

DALLAS, Oct. 4, 2011 /PRNewswire/ -- Goldfarb Branham LLP is investigating whether the board of directors of Pharmaceutical Product Development (NASDAQ: PPDI) violated shareholder protection laws by agreeing to sell the company for $33.25 per share. Concerned investors are encouraged to contact attorney Hamilton Lindley at 877-583-2855 or hlindley@goldfarbbranham.com about their rights and remedies.

"As recently as mid-August, shares of the company were trading at $32.20 per share," securities lawyer Hamilton Lindley said.  "Additionally, at least one analyst set a target price of $38.00 per share on the PPDI stock.  Our proposed shareholder class action lawsuit seeks to ensure that investors get the most value for their stock in this buyout."

Goldfarb Branham LLP lawyers have significant experience representing shareholders and whistleblowers in securities lawsuits nationwide. Pharmaceutical Product Development stockholders – or anyone with knowledge about this acquisition – should contact lawyer Hamilton Lindley at hlindley@goldfarbbranham.com or 877-583-2855.

Hamilton Lindley
Goldfarb Branham LLP
2501 N. Harwood, Ste. 1801
Dallas, TX 75201
(877) 583-2855 Toll Free Telephone
(214) 583-2233 Local Phone Number
(214) 583-2234 Fax Number
hlindley@goldfarbbranham.com
www.goldfarbbranham.com


'/>"/>
SOURCE Goldfarb Branham LLP
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. The Law Firm of Levi & Korsinsky, LLP Announces Investigation Into Possible Breaches of Fiduciary Duty by the Board of Pharmaceutical Product Development, Inc. in Connection With Sale of the Company to The Carlyle Group and Hellman & Friedman
2. Positive Phase III Data on Bayers Investigational Drug Radium-223 Chloride Show Significant Increase in Overall Survival
3. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
4. Bayer to Present New Data Evaluating Investigational Oncology Compounds at 2011 ECCO-ESMO Congress
5. Boehringer Ingelheim Broadens Its Breast Cancer Clinical Trial Program for the Investigational Compound Afatinib
6. FDA Grants Fast Track Designation to Bayers Investigational Compound Radium-223 Chloride for the Treatment of Castration-Resistant Prostate Cancer That Has Spread to the Bone
7. CoLucid Pharmaceuticals Receives Clearance for Investigational New Drug (IND) Application for Lasmiditan for the Treatment of Acute Migraine
8. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
9. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
10. Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Associations 71st Annual Scientific Sessions
11. UCB, Inc. Resolves Investigation of Past Keppra® Marketing and Promotional Activities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , Feb. 9, 2016 The new report "Global Blood Monitoring ... Acuity Business Research & Consulting group reveals that global market for ... million in 2014 and expected to grow to US$ 24,830.1 million ... North America , Europe ... , Middle-East and Africa ...
(Date:2/9/2016)... BRUNSWICK, N.J. , Feb. 9, 2016  Johnson ... the RBC Capital Markets Global Healthcare Conference on Tuesday, ... York City.  Dominic Caruso , Vice President, Finance ... Worldwide Chairman, Consumer will represent the Company in a ... www.investor.jnj.com . --> www.investor.jnj.com . ...
(Date:2/9/2016)... , Feb. 9, 2016  Bluestar Silicones will promote ... line for long-term implant applications and announce certification ... & Manufacturing (MD&M) West Conference (Booth #1759), February ... --> --> Available in ... LSRs offer outstanding physical properties enabling our customers ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... February is Heart Awareness ... Rate Variability scans throughout the month to the American Heart Association, New Mexico chapter. ... signs of heart disease and Health Quest’s INSiGHT Pulse Wave Profiler utilizes a non-invasive ...
(Date:2/9/2016)... ... February 09, 2016 , ... A new study ... rates and Medicare rates for a variety of medical services in Illinois as ... of the 2015 Fee Schedule Rates in Illinois, are professional medical services, ...
(Date:2/9/2016)... California (PRWEB) , ... February ... ... automated print and e-book publishing software, in partnership with Snowfall4pod Digital, creators ... – a comprehensive book publishing, content management, global distribution and print-on-demand network. ...
(Date:2/9/2016)... ... February 09, 2016 , ... Establishment Labs, a global breast implant ... to the company´s Board of Directors. , “We are honored to welcome ... exceptional entrepreneur.” said Juan Jose Chacon Quiros, CEO of Establishment Labs. "David’s knowledge and ...
(Date:2/9/2016)... ... ... Journal of Pain Research has published the commentary “ Terminology of chronic ... John F. Peppin says “Terminology matters, yet little attention has been paid to the ... pain’ and ‘chronic non-cancer pain’ are replete in the literature; however, the distinction here ...
Breaking Medicine News(10 mins):